Fortitude Family Office’s Sarepta Therapeutics SRPT Stock Holding History

Fortitude Family Office’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3	Closed	-$51	–	2132
2025 Q2	$51	Buy	+3	New	+$128	﹤0.01%	2015

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Fortitude Family Office's SRPT Position: Q3 2025 in Review

Fortitude Family Office sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 3 shares — an estimated $51 sold.

Fortitude Family Office first reported a position in SRPT in Q2 2025 and held it in 1 quarter. The position peaked at $51 in Q2 2025. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

Fortitude Family Office reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
Fortitude Family Office sold 3 Sarepta Therapeutics shares in Q3 2025, an estimated $51.
Fortitude Family Office first reported a position in Sarepta Therapeutics in Q2 2025 and held it in 1 quarter.
Fortitude Family Office's Sarepta Therapeutics position peaked at $51 in Q2 2025.
319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Fortitude Family Office's 13F filing for Q3 2025, filed 17 Oct 2025.